Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK

Yantai, China, October 7, 2025 – Boan Biotech today announced that the Marketing Authorization Applications (MAAs) for its two denosumab injections, BA6101, a 60 mg denosumab injection for ortho...

BA1104 Phase III Trial in China Completes Patient Enrollment

Boan Biotech today announced that all the patients have been enrolled in a Phase III clinical trial of its nivolumab injection code-named BA1104 in China. This is China’s first biosimilar of Opd...

VOLUNTARY ANNOUNCEMENT THE ENROLLMENT FOR PHASE III TRIAL OF THE COMPANY'S NIVOLUMAB INJECTION HAS BEEN COMPLETED IN CHINA

Boan Biotech Presents Early Findings about BA1301 at ESMO 2025

Boan Biotech today announced that the preliminary results of the ongoing Phase I clinical study for its BA1301, an investigational antibody-drug conjugate (ADC), were recently presented at the 2025 Co...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025

Articles of Association

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

INTERIM REPORT 2025

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025

Boan Biotech Announces 2025 Half-Year Results

Boan Biotech (6955.HK) today announced its 2025 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 393 million, up 8% YoY, and the contribut...